The food and drug administration has the legal basis to restrict promotion of flawed comparative effectiveness research

Health Affairs

Volumn 31, Issue 10, 2012, Pages 2200-2205

  Kesselheim, Aaron S ^a   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

ARTICLE; COMPARATIVE EFFECTIVENESS; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; OBSERVATIONAL STUDY; PHARMACOEPIDEMIOLOGY;

COMPARATIVE EFFECTIVENESS RESEARCH; GOVERNMENT REGULATION; HUMANS; MARKETING; QUALITATIVE RESEARCH; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84871959499     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2012.0787     Document Type: Article

References (25)

1. Dentzer S. Communicating about comparative effectiveness research: a Health Affairs symposium on the issues. Health Aff (Millwood). 2012;31(10):2183-87.
2. Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA. 2011;305:2320-6.
3. Jackson JD. FDAMA 1997 section 114: another look. Value in Health. 2010;12:191-2.
4. CFR 202.1(e)(4)(ii)(c).
5. Food and Drug Administration. Guidance for industry: hypertension indication: drug labeling for cardiovascular outcome claims [Internet]. Silver Spring (MD): FDA; 2011 Mar [cited 28 Aug 2012]. Available from: http://www.fda.gov/downloads/ Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ ucm075072.pdf
6. Food and Drug Administration. Good reprint practices for the distribution of medical journal articles and medical or scientific reference publications on unapproved new uses of approved drugs and approved or cleared medical devices [Internet]. Silver Spring (MD): FDA; 2009 Jan [cited 28 Aug 2012]. Available from: http://www.fda.gov/ RegulatoryInformation/Guidances/ ucm125126.htm
7. Temple R. Communication of CER findings [Internet]. Silver Spring (MD): FDA; 2012 Feb 9 [cited 28 Aug 2012]. Available from: http:// www.npcnow.org/App_Themes/ Public/pdf/events/2012asymmetry/ rtemple_asym12.pdf
8. Fischer M, Avorn J. Academic detailing can play a key role in assessing and implementing comparative effectiveness research. Health Aff (Millwood). 2012;31 (10):2206-12.
9. Panholzer L. RE: NDA #s 20-628, 21-785 (Invirase (saquinavir mesylate) capsules and tablets) [Internet]. Washington (DC): Department of Health and Human Services; 2010 Apr 8 [cited 2012 Aug 28]. Available from: http:// www.fda.gov/downloads/drugs/ guidancecomplianceregulatory information/enforcement activitiesbyfda/warningletters andnoticeofviolationlettersto pharmaceuticalcompanies/ ucm209517.pdf
10. Avorn J. In defense of pharmacoepidemiology- embracing the yin and yang of drug research. N Engl J Med. 2007;357(22):2219-21.
11. Ray WA. Evaluating medication effects outside of clinical trials: newuser designs. Am J Epidemiology. 2003;158(9):915-20.
12. Madigan D, Sigelman DW, Mayer JW, Furberg CD, Avorn J. Underreporting of cardiovascular events in the rofecoxib Alzheimer disease studies. Am Heart J. 2012;164(2): 186-93.
13. Kesselheim AS, Mello MM, Studdert DM. Strategies and practices in offlabel marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med. 2011; 8(4):e1000431.
14. Marks HM. The progress of experiment: science and therapeutic reform in the United States, 1900-1990. Cambridge: Cambridge University Press; 2000.
15. Berger ML, Dreyer N, Anderson F, Towse A, Sedrakyan A, Normand SL. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. Value in Health. 2012;15(2):217-30.
16. International Society of Pharmacoepidemiology. GRACE principles: good research for comparative effectiveness [Internet]. Bethesda (MD): ISPE; 2010 Apr 10 [cited 2012 Aug 28]. Available from: http:// www.pharmacoepi.org/resources/ GRACE_Principles.pdf
17. Blake KV, Devries CS, Arlett P, Kurz X, Fitt H. Increasing scientific standards, independence, and transparency in post-authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiol Drug Saf. 2012;21(7): 690-6.
18. Schneeweiss S, Avorn J. Postmarketing studies of drug safety. BMJ. 2011;342:d342.
19. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database-update and key issues. N Engl J Med. 2011;364: 852-60.
20. Berger ML, Grainger D. Comparative effectiveness research: the view from a pharmaceutical company. Pharmacoeconomics. 2010;28(10): 915-22.
21. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4):512-22.
22. Washington Legal Foundation. The Honorable Dick Thornburgh, Harvey Ashman, Paul Clement. Conversations with... [serial on the Internet]. Winter 2012 [cited 2012 Aug 2012]. Available from: http://www.wlf.org/ upload/legalstudies/conversations with/AshmanFeb16Draft_draft.pdf
23. Citizens United v. Federal Election Commission, 558 U.S. 50 (2010).
24. Klasmeier C, Redish MH. Off-label prescription advertising, the Food and Drug Administration, and the First Amendment: a study in the values of commercial speech protection. Am J Law Med. 2011; 37(2-3):315-57.
25. Kesselheim AS, Avorn J. Pharmaceutical promotion to physicians and First Amendment rights. N Engl J Med. 2008;358:1727-32.